AMNOG data 2023: Proven price regulation facing risky upheaval
23.11.2023 15:15
After twelve years, the AMNOG has largely proven itself in practice. The authors of the AMNOG data 2023 from the Federal Association of the Pharmaceutical Industry eV also come to this conclusion: “Designed as a “learning system” from the start, it is now considered adaptable and functional despite some birth defects that have not yet been corrected, questionable results and undesirable side effects “, write the health economists Professor Dieter Cassel and Professor Volker Ulrich.
However, it is more than questionable whether it will continue to prove itself in the future as an instrument for the fair balancing of interests in innovative medicines and thus also as a door opener for patients' access to new medicines. “The legislature remains stuck in old cost containment patterns,” write Cassel and Ulrich with a view to the GKV Financial Stabilization Act (GKV-FinStG), which was passed at the end of 2022. This has little to do with “more sustainable financing that also takes into account the performance side or incentive improvements”. In fact, with the latest revision of AMNOG, its basic principle of “Money for Value” is simply thrown overboard: the goal is no longer to reward therapeutic progress, but to contain costs wherever possible.
The AMNOG data 2023 refer to the results of the benefit assessment and pricing of drug innovations before the GKV-FinStG came into force and therefore do not yet reflect the effects of the new legislation. It will be exciting to be able to prove this in the next edition. “The new “guardrails” are likely to affect four out of five new drugs in the future and will therefore even exceed the legislator's expected savings of 250 to 300 million euros,” Professors Cassel and Ulrich point out.
The “AMNOG data”, written by Cassel and Ulrich for the sixth year and published by the BPI, provides detailed information about the basics, processes and results of the additional benefit assessment and pricing of innovative prescription drugs in Germany and addresses critical aspects of AMNOG regulation: How many procedures have there been before? How often were the new preparations recognized as having additional benefits? Are there any special assessment features in individual therapeutic areas? How does the benefit assessment affect the reimbursement amount agreements? What results do the arbitration proceedings lead to? Does this result in undesirable side effects on patient care? How are the prices for drug innovations developing? And last but not least: How do the expenditure shares of innovative medicines develop over time?
You can view the AMNOG data 2023 and all associated images directly via the Homepage Download the BPI, read it in the BPI kiosk or order it as a free brochure from the BPI office.